Lantheus (LNTH)
NASDAQ:LNTH
Want to see LNTH full AI Analyst Report?
LNTH Stock Chart & Stats
$83.82
-$2.32(-2.39%)
At close: 4:00 PM EST
$83.82
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $108.91
Previous CloseN/A
Volume177.90K
Average Volume (3M)941.39K
Market Cap
$5.57B
Enterprise Value$5.60B
Total Cash (Recent Filing)$359.12M
Total Debt (Recent Filing)$673.25M
Price to Earnings (P/E)19.2
Beta0.60
Next Earnings
May 07, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding65,102,600
10 Day Avg. Volume691,671
30 Day Avg. Volume941,386
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit5.94
Enterprise Value/Ebitda13.87
Forecast
1Y Price Target
$95.00Price Target Upside13.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)5.19
Revenue Forecast (FY)$1.45B
Bulls Say, Bears Say
Bulls Say
Manufacturing CapacityNew formulation expands batch capacity and manufacturing efficiency, improving supply readiness and supporting a commercial rollout that could drive meaningful revenue growth.
Regulatory ClarityRegulatory review issues tied to manufacturing rather than clinical safety reduce concern about product safety and support expectations that manufacturing fixes could enable approval.
Reimbursement ProspectsApproval of a new fluorinated PSMA PET agent increases the likelihood of transitional pass-through reimbursement, which could improve pricing and product mix and help stabilize the flagship franchise as a competitor's temporary reimbursement expires.
Bears Say
Delayed Pipeline BenefitsRecent approvals and pipeline assets are unlikely to produce meaningful near-term revenue, creating a setup period without immediate sales benefit and increasing execution risk.
Near-term Revenue HeadwindsRevenue guidance implies a decline driven by increased competition for core products, putting pressure on near-term sales and limiting upside.
Pricing Pressure And Volume DeclineOngoing pricing erosion is expected to outweigh modest volume gains, contributing to declining flagship product sales and lower imaging dose volumes that heighten revenue risk.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $47.25 and its highest was $108.91 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $5.57B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is May 07, 2026 which is in 3 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Feb 26, 2026. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.194 by $0.476.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.23.
How many shares outstanding does Lantheus have?
Lantheus has 65,102,600 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.67 in its last earnings report, beating expectations of $1.194. Following the earnings report the stock price went down -0.383%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.00 (13.34% Upside)
$95.00 (13.34% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.27%
12-Months-Change
Fundamentals
Return on Equity
20.58%
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$95.00
▲(13.34% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
12.63% Insiders
34.97% Mutual Funds
6.59% Other Institutional Investors
17.45% Public Companies and
Individual Investors